PL3186283T3 - Terapia skojarzona z zastosowaniem skierowanej przeciw nowotworowi, opartej na wariancie IL2 immunocytokiny oraz przeciwciał przeciwko ludzkiemu ligandowi programowanej śmierci PD-L1 - Google Patents

Terapia skojarzona z zastosowaniem skierowanej przeciw nowotworowi, opartej na wariancie IL2 immunocytokiny oraz przeciwciał przeciwko ludzkiemu ligandowi programowanej śmierci PD-L1

Info

Publication number
PL3186283T3
PL3186283T3 PL15753700T PL15753700T PL3186283T3 PL 3186283 T3 PL3186283 T3 PL 3186283T3 PL 15753700 T PL15753700 T PL 15753700T PL 15753700 T PL15753700 T PL 15753700T PL 3186283 T3 PL3186283 T3 PL 3186283T3
Authority
PL
Poland
Prior art keywords
tumor
targeted
combination therapy
antibodies against
against human
Prior art date
Application number
PL15753700T
Other languages
English (en)
Inventor
Pablo Umana
Christian Klein
Valeria G. Nicolini
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL3186283T3 publication Critical patent/PL3186283T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
PL15753700T 2014-08-29 2015-08-25 Terapia skojarzona z zastosowaniem skierowanej przeciw nowotworowi, opartej na wariancie IL2 immunocytokiny oraz przeciwciał przeciwko ludzkiemu ligandowi programowanej śmierci PD-L1 PL3186283T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14182778 2014-08-29
EP15753700.2A EP3186283B1 (en) 2014-08-29 2015-08-25 Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
PCT/EP2015/069399 WO2016030350A1 (en) 2014-08-29 2015-08-25 Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1

Publications (1)

Publication Number Publication Date
PL3186283T3 true PL3186283T3 (pl) 2020-05-18

Family

ID=51535312

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15753700T PL3186283T3 (pl) 2014-08-29 2015-08-25 Terapia skojarzona z zastosowaniem skierowanej przeciw nowotworowi, opartej na wariancie IL2 immunocytokiny oraz przeciwciał przeciwko ludzkiemu ligandowi programowanej śmierci PD-L1

Country Status (24)

Country Link
US (3) US20160175397A1 (pl)
EP (1) EP3186283B1 (pl)
JP (3) JP6603707B2 (pl)
KR (1) KR102058846B1 (pl)
CN (1) CN106794245B (pl)
AR (1) AR101697A1 (pl)
AU (1) AU2015308527C1 (pl)
BR (1) BR112016030670A2 (pl)
CA (1) CA2951604A1 (pl)
DK (1) DK3186283T3 (pl)
ES (1) ES2774380T3 (pl)
HR (1) HRP20200272T1 (pl)
HU (1) HUE047806T2 (pl)
IL (1) IL249162B (pl)
LT (1) LT3186283T (pl)
MX (1) MX379475B (pl)
MY (1) MY193723A (pl)
PL (1) PL3186283T3 (pl)
PT (1) PT3186283T (pl)
RS (1) RS59939B1 (pl)
RU (1) RU2710354C2 (pl)
SG (1) SG11201701157UA (pl)
SI (1) SI3186283T1 (pl)
WO (1) WO2016030350A1 (pl)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
KR101981342B1 (ko) * 2011-03-02 2019-05-22 로슈 글리카트 아게 Cea 항체
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
KR101870555B1 (ko) 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
MX2015003616A (es) 2012-10-08 2015-06-05 Roche Glycart Ag Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso.
SG11201504558TA (en) 2012-12-11 2015-07-30 Einstein Coll Med Methods for high throughput receptor:ligand identification
CN110437337B (zh) 2013-02-26 2024-07-30 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP6592505B2 (ja) 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
PL3177643T3 (pl) 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
ES2774380T3 (es) * 2014-08-29 2020-07-20 Hoffmann La Roche Politerapia de inmunocitocinas de variante de IL-2 dirigida a tumor y anticuerpos frente a PD-L1 humano
ES2808853T3 (es) 2014-11-20 2021-03-02 Hoffmann La Roche Cadenas ligeras comunes y procedimientos de uso
SG11201704056XA (en) 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
RS61010B1 (sr) 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
JP7044700B2 (ja) 2015-10-02 2022-03-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ｃｅａｘｃｄ３ ｔ細胞活性化抗原結合分子
IL313608A (en) 2015-12-09 2024-08-01 Hoffmann La Roche Antibody against CD20 type II to reduce the formation of antibodies against drugs
BR112018011029A2 (pt) 2016-01-08 2018-11-21 Hoffmann La Roche métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
JP7015244B2 (ja) 2016-03-22 2022-02-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト プロテアーゼ活性化ｔ細胞二重特異性分子
SG11201808552XA (en) 2016-05-18 2018-10-30 Cue Biopharma Inc T-cell modulatory multimeric polypeptides and methods of use thereof
IL262606B2 (en) 2016-05-18 2023-04-01 Albert Einstein College Medicine Inc pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them
KR102543118B1 (ko) 2016-05-27 2023-06-14 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
KR102379464B1 (ko) * 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
RU2764548C2 (ru) 2016-08-09 2022-01-18 Кимаб Лимитед Анти-icos антитела
US10858428B2 (en) 2016-09-28 2020-12-08 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
CN109843926B (zh) 2016-09-30 2023-01-20 豪夫迈·罗氏有限公司 针对cd3的双特异性抗体
BR112019006504A2 (pt) * 2016-10-06 2019-06-25 Pfizer Inc. regime de dosagem de avelumabe para o tratamento de câncer
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
JP7125400B2 (ja) 2016-12-19 2022-08-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 標的化４－１ｂｂ（ｃｄ１３７）アゴニストとの併用療法
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
CA3047070A1 (en) 2017-01-03 2018-07-12 F.Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
AU2018207172B2 (en) 2017-01-13 2023-10-12 Mink Therapeutics, Inc. T cell receptors that bind to NY-ESO-1 and methods of use thereof
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
WO2018178055A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
KR102461885B1 (ko) 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
CN110402255B (zh) 2017-04-04 2022-12-02 豪夫迈·罗氏有限公司 新颖的能够特异性结合cd40和fap的双特异性抗原结合分子
KR20190136076A (ko) * 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc. anticorpos anti-cd137 e métodos de uso dos mesmos
LT3618863T (lt) 2017-05-01 2023-10-10 Agenus Inc. Anti-tigit antikūnai ir jų panaudojimo būdai
CN108948195B (zh) * 2017-05-23 2022-05-31 胡毅 一种抗egfr/pd-l1双靶向抗体、其制备方法及用途
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
AU2018273914A1 (en) * 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
KR102920712B1 (ko) 2017-05-24 2026-01-30 노파르티스 아게 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
AU2018287317B2 (en) 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
US20200306301A1 (en) 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
WO2019046856A1 (en) 2017-09-04 2019-03-07 Agenus Inc. T-CELL RECEPTORS THAT BIND TO SPECIFIC PHOSPHOPEPTIDES OF MIXED LINEAR LEUKEMIA (MLL) AND METHODS OF USE THEREOF
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
MX2020002596A (es) * 2017-09-07 2020-07-20 Cue Biopharma Inc Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos.
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CA3090406A1 (en) 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
CR20200391A (es) 2018-02-08 2020-10-19 Genentech Inc Moléculas biespecíficas de unión al antígeno y métodos de uso
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
CR20200459A (es) 2018-04-13 2020-11-11 Hoffmann La Roche Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl
EP3784688A2 (en) 2018-04-26 2021-03-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
EP3802587A4 (en) * 2018-06-07 2022-03-23 Prottech Inc. PHARMACEUTICAL COMPOSITION WITH A FUSION PROTEIN AND THEIR USE
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
CA3109139A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Methods of treating aging-related disorders
CN112996805A (zh) 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
WO2020047333A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CN109053891B (zh) 2018-09-17 2021-12-21 苏州泓迅生物科技股份有限公司 一种抗pd-l1抗体及其制备方法和应用
SG11202005873QA (en) 2018-09-17 2020-07-29 Gi Innovation Inc Fusion protein comprising il-2 protein and cd80 protein, and use thereof
US20220008526A1 (en) * 2018-11-15 2022-01-13 Torque Therapeutics, Inc. Methods and compositions for cancer immunotherapy
EP3897746A4 (en) * 2018-12-19 2022-10-26 Cue Biopharma, Inc. MULTIMERIC T LYMPHOCYTE MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
WO2020198665A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Fibroblast activation protein binding agents and use thereof
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
AU2020294797B2 (en) 2019-06-21 2025-12-18 Immunitybio, Inc. Multi-chain chimeric polypeptides and uses thereof
EP3990492A1 (en) 2019-06-27 2022-05-04 F. Hoffmann-La Roche AG Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
AR119382A1 (es) * 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
CN114585644A (zh) 2019-08-30 2022-06-03 艾吉纳斯公司 抗cd96抗体及其使用方法
CN114599396A (zh) * 2019-10-11 2022-06-07 庆北大学校产学协力团 包含外泌体pd-l1的表达抑制剂作为活性成分的用于增强抗癌作用的组合物
KR102548440B1 (ko) * 2019-10-11 2023-06-28 경북대학교 산학협력단 엑소좀 pd-l1의 발현에 대한 억제제를 유효성분으로 포함하는 항암 효과 증진용 조성물
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
KR102559355B1 (ko) * 2020-01-31 2023-07-25 주식회사 제넥신 항-taa 항체, 항-pd-l1 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
WO2021163299A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Chromatography resin and uses thereof
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
CN116670163A (zh) * 2020-02-11 2023-08-29 Hcw生物科技公司 治疗年龄相关疾病和炎性疾病的方法
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
TWI855242B (zh) 2020-03-18 2024-09-11 南韓商Ｇｉ醫諾微新股份有限公司 包含含有il-2蛋白與cd80蛋白之融合蛋白及抗癌藥物的用於治療癌症的藥學組成物
AU2021262794B2 (en) 2020-04-29 2026-06-18 Immunitybio, Inc. Anti-CD26 proteins and uses thereof
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
KR20230010251A (ko) 2020-05-13 2023-01-18 보넘 테라퓨틱스, 인크. 단백질 복합체의 조성물 및 그의 사용 방법
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
CR20220637A (es) 2020-06-19 2023-01-31 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
WO2022008688A1 (en) * 2020-07-10 2022-01-13 F. Hoffmann-La Roche Ag Antibodies which bind to cancer cells and target radionuclides to said cells
JP2022045530A (ja) * 2020-09-09 2022-03-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－１標的化ｉｌ－２変異体免疫サイトカインとヒトｐｄ－ｌ１に対する抗体との併用療法
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
US11865082B2 (en) 2020-09-09 2024-01-09 Hoffmann-La Roche Inc. Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
JP2024504372A (ja) * 2021-01-22 2024-01-31 エルピス・バイオファーマシューティカルズ 抗ｐｄ－ｌ１モノクローナル抗体及びインターロイキン１５（ｉｌ－１５）、インターロイキン１５受容体１５アルファまたはインターロイキン２との融合タンパク質
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
JP7849832B2 (ja) 2021-08-06 2026-04-22 国立大学法人 長崎大学 がんの治療剤
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
CR20240246A (es) * 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
AU2023226512A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
EP4499229A1 (en) 2022-03-28 2025-02-05 F. Hoffmann-La Roche AG Interferon gamma variants and antigen binding molecules comprising these
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US12594323B2 (en) 2022-04-13 2026-04-07 Immunitybio, Inc. Methods of reducing neuroinflammation
CN119790064A (zh) * 2022-08-23 2025-04-08 马斯得生物有限公司 Il2变体和包括该il2变体的蛋白复合体
CN119948048A (zh) * 2022-09-29 2025-05-06 豪夫迈·罗氏有限公司 蛋白酶活化的多肽
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
CN116162171B (zh) * 2022-10-13 2025-06-03 深圳市百士通科技开发有限公司 抗体突变方法在治疗性抗体药物中的应用
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
EP4694894A1 (en) 2023-04-12 2026-02-18 Agenus Inc. Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
CN121729432A (zh) 2023-06-23 2026-03-24 派克西斯肿瘤学公司 抗klrg1抗体及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010912A1 (en) * 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
WO2007076923A1 (en) * 2006-01-04 2007-07-12 Merck Patent Gmbh Combination therapy using anti-egfr and anti-her2 antibodies
MX356367B (es) * 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
CN105440123B (zh) * 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
WO2012125850A1 (en) * 2011-03-16 2012-09-20 Amgen Inc. Fc variants
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CN102199218A (zh) * 2011-04-29 2011-09-28 中国人民解放军军事医学科学院基础医学研究所 一种抗Her2抗体-白细胞介素2融合蛋白及其用途
PL3434695T3 (pl) * 2012-08-07 2021-05-17 Roche Glycart Ag Ulepszona immunoterapia
ES2774380T3 (es) * 2014-08-29 2020-07-20 Hoffmann La Roche Politerapia de inmunocitocinas de variante de IL-2 dirigida a tumor y anticuerpos frente a PD-L1 humano

Also Published As

Publication number Publication date
MX2017002426A (es) 2017-06-20
MX379475B (es) 2025-03-11
LT3186283T (lt) 2020-03-10
US20180200338A1 (en) 2018-07-19
JP6603707B2 (ja) 2019-11-06
AU2015308527B2 (en) 2021-03-11
RU2017110279A3 (pl) 2019-02-27
RU2017110279A (ru) 2018-10-04
AU2015308527C1 (en) 2021-07-15
AR101697A1 (es) 2017-01-04
HUE047806T2 (hu) 2020-05-28
SG11201701157UA (en) 2017-03-30
MY193723A (en) 2022-10-27
CN106794245A (zh) 2017-05-31
IL249162A0 (en) 2017-01-31
BR112016030670A2 (pt) 2017-10-31
HRP20200272T1 (hr) 2020-05-29
KR20170032461A (ko) 2017-03-22
ES2774380T3 (es) 2020-07-20
PT3186283T (pt) 2020-02-21
SI3186283T1 (sl) 2020-04-30
CN106794245B (zh) 2021-06-01
JP6594573B2 (ja) 2019-10-23
CA2951604A1 (en) 2016-03-03
JP2019108341A (ja) 2019-07-04
JP2017530102A (ja) 2017-10-12
RS59939B1 (sr) 2020-03-31
US20160175397A1 (en) 2016-06-23
US20190374609A1 (en) 2019-12-12
IL249162B (en) 2021-04-29
KR102058846B1 (ko) 2020-02-20
EP3186283A1 (en) 2017-07-05
JP2020033362A (ja) 2020-03-05
WO2016030350A1 (en) 2016-03-03
AU2015308527A1 (en) 2016-12-15
RU2710354C2 (ru) 2019-12-25
DK3186283T3 (da) 2020-03-02
EP3186283B1 (en) 2019-12-25

Similar Documents

Publication Publication Date Title
IL249162A0 (en) Combination therapy of il2 variant tumor-directed immunocytokines and antibodies against human pd-l1
HUS2500022I1 (hu) Terápiás ellenanyagok és alkalmazásaik
IL249189A0 (en) Combined treatment of antibodies against human cd40 and antibodies against human pd-l1
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL248455B (en) igf-1r antibody-drug conjugate and its use for cancer treatment
GB201403093D0 (en) Therapeutic compounds and their use
SI3356404T1 (sl) Protitelesa proti PD1 in postopki uporabe
EP3137096A4 (en) Enamel products and methods of use
GB201404470D0 (en) Therapeutic methods and materials
IL246757A0 (en) New insulin histories and their medical uses
EP3188721A4 (en) Human therapeutic agents
EP3113771A4 (en) Therapeutic uses of ibogaine and related compounds
EP3169321A4 (en) Propolis and extracts thereof for the treatment of skin cancers and improvement of skin health
EP3226817A4 (en) Traction splints and methods of using traction splints
GB201617064D0 (en) Compounds and their therapeutic use
EP3302530A4 (en) Cdh26 based therapeutic agents and their use
GB201423270D0 (en) The combination for soothing and repair of the skin
EP3166406A4 (en) Cytokine-chitosan bioconjugates and methods of using the same
EP3204003A4 (en) Selenosugars and therapeutic uses thereof
GB201522992D0 (en) The health care products with the function of therapy
EP3212202A4 (en) Use of therapeutic agents
AU2014901476A0 (en) Patient Interface and Components Thereof
GB201410387D0 (en) Compounds and their therapeutic use
GB201403496D0 (en) Compounds and their therapeutic use
AU2014901940A0 (en) Formulations and Therapeutic Uses Thereof